Monday, September 24, 2007

Mapp Biopharmaceutical Announcement an Example of Owensboro’s Competitive Advantage in Plant Natural Product Production

The announcement last week that Mapp Biopharmaceutical, Inc will expand operations to the Kentucky Bioprocessing (KBP) campus in Owensboro is a good example of the potential Owensboro has to become a world center of plant natural product production.

Mapp will utilize the facility and the workforce at KBP as part of its focus on development of a commercial scale production platform for its products. Headquartered in San Diego, CA, Mapp has developed and is currently producing several different plant derived products for use in small volume trials. The expansion to the KBP campus is intended to allow Mapp to leverage the unique expertise and capability of KBP to develop full scale production methods for its products, enabling clinical trials and ultimately product commercialization.

What does all this mean? It means that KBP in Owensboro, Kentucky offers to this company-- headquartered in the heart of one of the world’s most fabled biotech clusters-- a competitive advantage that no one else in the world offers: the ability to develop commercial scale production of plant derived products. The competitive advantage is the KBP facility, its personnel, and intellectual property. No other place in the world can successfully bring to commercial scale a plant-based product as efficiently and effectively as in Owensboro, Kentucky.

KBP offers clients and collaborators access to controlled plant growth facilities along with bench, pilot and full scale processing facilities all capable of production. In addition to its own capabilities KBP is able to leverage the experienced staff and facilities of the Owensboro Cancer Research Program and provides linkages to the considerable plant made product expertise of the Owensboro area agriculture community and to other services offered throughout the region designed to support research, development and growth of a plant made product business cluster.

In the 21st century innovation-based economy, the fact that we have the facility, the people and the intellectual property is significant. Make no mistake; we are not trying to become a biotech cluster to compete with the likes of San Diego or Boston. But we can succeed in creating a cluster of companies focusing on the utilization of our strengths, plant pharmaceuticals and plant-based natural products. In this area between KBP, the Owensboro Cancer Research Program and the partnership with the University of Louisville, and our regional agriculture community, we have a competitive advantage not found anywhere else. For more information about the Owensboro Life Science Partnership please visit

No comments: